WCG Randomized 1,600 Participants for RSV Vaccine Trial

News
Article

Sponsored Content

A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.

Related Content
© 2024 MJH Life Sciences

All rights reserved.